Mode
Text Size
Log in / Sign up

Prospective paired-sample study reviews AveloMask XBA sampling versus lower respiratory tract specimens in hospitalized pneumonia patientsYour Breath Could Diagnose Pneumonia Without a Needle

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that AveloMask XBA sampling showed 95% overall agreement with LRT specimens but lower positive percent agreement for viruses.

This prospective paired-sample study assessed the concordance of exhaled breath aerosol (XBA) sampling using the AveloMask against lower respiratory tract (LRT) specimens, such as sputum or bronchoalveolar lavage, in a cohort of 93 enrolled hospitalized adults with pneumonia. Paired samples were provided by 63 participants across three hospitals in Switzerland and Georgia. The primary outcome measured positive, negative, and overall percent agreement between XBA and LRT samples.

Among the 47 LRT-positive cases, the dominant pathogen was identified in 40 instances, yielding an 85.1% identification rate. Across all targets, positive percent agreement was 61% (95% CI, 50-72%), while negative percent agreement reached 100% (95% CI, 99-100%). Overall percent agreement across all targets was 95% (95% CI, 92-96%). The study did not report adverse events, discontinuations, or tolerability data.

The authors observed that positive percent agreement was higher for bacteria than for viruses, with lower agreement largely driven by reduced detection of low-abundance or co-infecting pathogens. The study was funded by an entity not reported in the source text. While breath aerosol sampling may complement conventional testing, particularly when sputum is unavailable, the findings should be interpreted with caution regarding antimicrobial de-escalation support.

BODY

Imagine being too sick to cough up mucus. Doctors need to know what germ is making you sick.

Pneumonia is a serious lung infection. It affects millions of people every year. Getting a sample usually hurts or is very hard.

Many patients struggle to produce enough sputum. Others need invasive procedures to get a sample. This delays treatment and causes stress.

Why breathing matters now

We used to need needles or deep coughing. Now, just breathing into a mask.

This study tested a special mask called the AveloMask. It collects tiny particles from your breath.

Standard tests often require a bronchoscopy. This involves putting a tube down your throat. It is uncomfortable and risky for some people.

The surprising shift in testing

Think of it like catching dust in the air. The mask traps tiny particles you breathe out.

Scientists use technology to find germs inside these particles. It is like finding a needle in a haystack.

The mask captures aerosols that come from deep in your lungs. These particles carry the germs causing the infection.

Catching germs without a needle

63 patients, 3 hospitals, compared mask to standard tests. Researchers looked at people with pneumonia in Switzerland and Georgia.

They used the mask and a standard sample at the same time. This allowed for a direct comparison.

The mask results were matched against the best available tests. This ensured the new method was accurate.

Good at finding the main germ. Missed some smaller ones.

The mask found the main germ in 85% of cases. It was very good at saying when there was no infection.

When the mask said negative, it was always correct. This means you can trust a negative result.

This doesn’t mean this treatment is available yet.

It missed some bacteria that were present in small amounts. It also struggled with multiple germs at once.

But it worked better for bacteria than for viruses. This is important for choosing the right medicine.

Experts say this could help doctors choose better antibiotics. It might reduce the need for invasive tests in the future.

This tool is still being tested for safety. You cannot buy this mask at a store today.

If you have pneumonia, ask about standard testing options. This tool is still being tested for safety.

Only 63 people provided paired samples for the study. The results need to be confirmed with more patients.

Researchers will test this on more people soon. Hospitals need to prove it works in different settings.

Regulatory bodies must review the data before approval. This process ensures the device is safe for everyone.

Approval takes time. This process ensures the device is safe for everyone.

Researchers will test this on more people soon. Hospitals need to prove it works in different settings.

Regulatory bodies must review the data before approval. This process ensures the device is safe for everyone.

Approval takes time. This process ensures the device is safe for everyone.

Study Details

Sample sizen = 63
EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Etiological diagnosis of lower respiratory tract infections (LRTIs) relies on sputum or bronchoalveolar lavage (BAL), which may be difficult to obtain or invasive. Exhaled breath aerosol (XBA) sampling offers a non-invasive alternative for pathogen detection. We evaluated the performance of the AveloMask, a face mask-based device designed to capture XBAs for molecular testing. In this prospective paired-sample study, hospitalized adults with pneumonia at three hospitals in Switzerland and Georgia provided an XBA sample using the AveloMask and a lower respiratory tract (LRT) specimen (sputum or BAL). XBA samples were analyzed by multiplex PCR using the Roche LightMix(R) panel and LRT samples were tested using the BioFire(R) FilmArray(R) Pneumonia Panel. Concordance between XBA and LRT samples was assessed using positive percent agreement (PPA), negative percent agreement (NPA), and overall percent agreement (OPA). Ninety-three participants were enrolled and 63 participants provided paired samples. AveloMask sampling identified the dominant pathogen (lowest Ct value in the LRT sample) in 40/47 LRT-positive cases (85.1%). Across all targets, PPA was 61% (95%CI, 50-72%), NPA was 100% (95%CI, 99-100%), and OPA was 95% (95% CI, 92-96%). PPA was higher for bacteria than for viruses and lower PPA was largely driven by reduced detection of low-abundance or co-infecting pathogens. In a subset analysis, AveloMask results showed substantial overlap with standard-of-care testing and could have supported antimicrobial de-escalation. Breath aerosol sampling using the AveloMask enabled non-invasive molecular detection of LRT pathogens in pneumonia cases and may complement conventional standard-of-care testing, particularly when sputum is unavailable.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.